In the spotlight: a novel CD37 antibody-drug conjugate
1MEMORIAL SLOAN-KETTERING CANCER CENTER.
Blood
|November 16, 2013
Abstract:
In this issue of Blood, Deckert et al make a strong argument in favor of IMGN529, a novel anti-CD37 maytansinoid antibody-drug conjugate (ADC), elegantly showing its activity against B-cell lymphoma in in vitro and in vivo preclinical studies.
